Ólanrewaju O. Okusanya

United States Food and Drug Administration

Also affiliated with Center for Drug Evaluation and Research

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation”.

FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4271

N/A

0DataRank · unranked

82 citations

Kelly J. Norsworthy, Yaping Wang, Qing Xu, Hisham Qosa, Ramadevi Gudi +8 more

FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic Therapy

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-4176

N/A

0DataRank · unranked

56 citations

Robert Q. Le, Alexei Ionan, Ruo‐Jing Li, Yinghong Wang, Ramadevi Gudi +16 more

FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-0618

N/A

0DataRank · unranked

56 citations

Rachel Ershler, Bindu Kanapuru, Qing Xu, Guoxiang Shen, Liang Li +8 more

FDA Approval Summary: Decitabine and Cedazuridine Tablets for Myelodysplastic Syndromes

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-4498

N/A

0DataRank · unranked

41 citations

Kelly J. Norsworthy, Sriram Subramaniam, Haiyan Chen, Michael L. Manning, Eliford Kitabi +8 more

FDA Approval Summary: Olutasidenib for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase 1 Mutation

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-2196

N/A

0DataRank · unranked

10 citations

Kelly J. Norsworthy, Moran Choe, Brenda J. Gehrke, Haiyan Chen, Jonathon Vallejo +12 more

Project Confirm: Accelerated Drug Approvals for CML—Response

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-3234

N/A

0DataRank · unranked

0 citations

Jörge E. Cortes, Jane F. Apperley, Mel Mann, Michael J. Mauro, Vivian G. Oehler +12 more

FDA Approval Summary: Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory Myelodysplastic Syndrome with an IDH1 Mutation

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1005

N/A

0DataRank · unranked

5 citations

Dianne Pulte, Xin Wang, Jonathon Vallejo, Ritu Chadda, Nan Zheng +10 more

FDA Approval Summary: Abatacept for the Prophylaxis of Acute GVHD

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-0688

N/A

0DataRank · unranked

3 citations

Donna R. Rivera, Joseph Wynne, Jian Zhao, Robyn Konicki, Aida Kuzucan +8 more

FDA–AACR Strategies for Optimizing Dosages for Oncology Drug Products: Early-Phase Trials Using Innovative Trial Designs and Biomarkers

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1918

N/A

0DataRank · unranked

3 citations

Gabriela Patilea-Vrana, Anthony Sireci, Alexia Iasonos, Brad A. Davidson, Jiang Liu +4 more